Psychedelic therapy (PT) may be beneficial for treating eating disorders and trauma-related conditions such as PTSD and dissociative amnesia. The abstract reviews how psilocybin could help patients remember and process traumatic memories, suggesting a mechanism for its therapeutic effects.
Psilocybin treatment shows promise for anorexia nervosa, a psychiatric illness with high mortality and limited treatment options, but studies remain preliminary. This article synthesizes first-hand experiences from 10 individuals with lived experience, offering thematic insights on the potential benefits and constraints of psilocybin treatment for anorexia. The authors contextualize these perspectives within their phase 1 pilot study findings, providing a nuanced exploration of how to optimize such treatments for this vulnerable population.
Interest in psychedelic-assisted therapy (PAT) is growing, prompting policy shifts toward legalization in many U.S. states. As PAT moves from controlled clinical trials to real-world practice, concerns arise about maintaining rigorous patient screening, treatment setting, and therapist support. Clinical trials use strict inclusion criteria and safety monitoring to minimize adverse events, but routine clinics may face pressure to lower standards, as seen in some for-profit ketamine clinics. Nonpharmacological factors like preparation, therapeutic rapport, and integration meaningfully shape outcomes. Standardized training, certification, and oversight, such as a FDA Risk Evaluation and Mitigation Strategy (REMS), could help balance safety and access. Successful implementation requires thorough screening, supportive environment, and careful regulation to realize PAT's potential in psychiatry.